345 related articles for article (PubMed ID: 15599804)
1. The past, present and future of antiviral drug discovery.
Littler E
IDrugs; 2004 Dec; 7(12):1104-12. PubMed ID: 15599804
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. New antivirals and drug resistance.
Colman PM
Annu Rev Biochem; 2009; 78():95-118. PubMed ID: 19254207
[TBL] [Abstract][Full Text] [Related]
4. The priorities for antiviral drug resistance surveillance and research.
Pillay D
J Antimicrob Chemother; 2007 Aug; 60 Suppl 1():i57-8. PubMed ID: 17656384
[TBL] [Abstract][Full Text] [Related]
5. Current non-AIDS antiviral chemotherapy.
Rottinghaus ST; Whitley RJ
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):217-30. PubMed ID: 17402837
[TBL] [Abstract][Full Text] [Related]
6. Acyclic nucleoside phosphonates: a key class of antiviral drugs.
De Clercq E; Holý A
Nat Rev Drug Discov; 2005 Nov; 4(11):928-40. PubMed ID: 16264436
[TBL] [Abstract][Full Text] [Related]
7. Metal chelators as antiviral agents.
Kirschberg T; Parrish J
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):460-72. PubMed ID: 17659488
[TBL] [Abstract][Full Text] [Related]
8. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
Tsantrizos YS
Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
[TBL] [Abstract][Full Text] [Related]
9. L-nucleoside enantiomers as antivirals drugs: a mini-review.
Mathé C; Gosselin G
Antiviral Res; 2006 Sep; 71(2-3):276-81. PubMed ID: 16797735
[TBL] [Abstract][Full Text] [Related]
10. Oligonucleotides as antivirals: dream or realistic perspective?
Van Aerschot A
Antiviral Res; 2006 Sep; 71(2-3):307-16. PubMed ID: 16621039
[TBL] [Abstract][Full Text] [Related]
11. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases.
Nijhuis M; van Maarseveen NM; Boucher CA
Handb Exp Pharmacol; 2009; (189):299-320. PubMed ID: 19048205
[TBL] [Abstract][Full Text] [Related]
12. Antiviral therapy: old and current issues.
Antonelli G; Turriziani O
Int J Antimicrob Agents; 2012 Aug; 40(2):95-102. PubMed ID: 22727532
[TBL] [Abstract][Full Text] [Related]
13. Recent developments in antiviral chemotherapy.
McKinlay MA; Otto MJ
Infect Dis Clin North Am; 1987 Jun; 1(2):479-93. PubMed ID: 3332799
[TBL] [Abstract][Full Text] [Related]
14. Antivirals: past, present and future.
De Clercq E
Biochem Pharmacol; 2013 Mar; 85(6):727-44. PubMed ID: 23270991
[TBL] [Abstract][Full Text] [Related]
15. Antiviral therapies in children: has their time arrived?
Kimberlin DW
Pediatr Clin North Am; 2005 Jun; 52(3):837-67, vii. PubMed ID: 15925665
[TBL] [Abstract][Full Text] [Related]
16. The design of drugs for HIV and HCV.
De Clercq E
Nat Rev Drug Discov; 2007 Dec; 6(12):1001-18. PubMed ID: 18049474
[TBL] [Abstract][Full Text] [Related]
17. [Antiviral chemotherapy in pediatrics--its present and prospects].
Arion C; Zamfirescu A; Popescu V
Pediatrie (Bucur); 1992; 41(1):46-52. PubMed ID: 1322725
[TBL] [Abstract][Full Text] [Related]
18. Looking back in 2009 at the dawning of antiviral therapy now 50 years ago an historical perspective.
De Clercq E
Adv Virus Res; 2009; 73():1-53. PubMed ID: 19695380
[TBL] [Abstract][Full Text] [Related]
19. Perspectives on antiviral drug development.
Wainberg MA
Antiviral Res; 2009 Jan; 81(1):1-5. PubMed ID: 18948140
[TBL] [Abstract][Full Text] [Related]
20. Phosprenyl: a novel drug with antiviral and immunomodulatory activity.
Danilov LL; Maltsev SD; Deyeva AV; Narovlyansky AN; Sanin AV; Ozherelkov SV; Pronin AV
Arch Immunol Ther Exp (Warsz); 1996; 44(5-6):395-400. PubMed ID: 9017158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
